Allison M Bock, Raphael Mwangi, Yucai Wang, Arushi Khurana, Matthew J Maurer, Amy Ayers, Brad S Kahl, Peter Martin, Jonathon B Cohen, Carla Casulo, Izidore S Lossos, Umar Farooq, Sabarish Ayyappan, Tanner Wayne Reicks, Thomas M Habermann, Thomas E Witzig, Christopher R Flowers, James R Cerhan, Loretta J Nastoupil, Grzegorz S Nowakowski
Patients with large B-cell lymphoma (LBCL) that fail to achieve a complete response (CR) or relapse early after anthracycline-containing immunochemotherapy (IC) have a poor prognosis and are commonly considered "primary refractory disease". However, different definitions of primary refractory disease are used in the literature and clinical practice. In this study, we ex-amined variation in the time to relapse used to define refractory status and association with sur-vival outcomes in patients with primary refractory LBCL in a single-center prospective cohort with a validation in an independent multi-center cohort...
April 26, 2024: Blood Advances